<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304083</url>
  </required_header>
  <id_info>
    <org_study_id>SARC006</org_study_id>
    <secondary_id>SARC-006</secondary_id>
    <secondary_id>NCI-06-C-0043</secondary_id>
    <secondary_id>NCI-P6452</secondary_id>
    <secondary_id>UMN-2007CG077</secondary_id>
    <nct_id>NCT00304083</nct_id>
    <nct_alias>NCT00266890</nct_alias>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors</brief_title>
  <official_title>Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarcoma Alliance for Research through Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sarcoma Alliance for Research through Collaboration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and etoposide, work
      in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
      Giving combination chemotherapy with or without radiation therapy before surgery may make the
      tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving
      combination chemotherapy after surgery may kill any tumor cells that remain after surgery.

      PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating
      patients with stage III or stage IV malignant peripheral nerve sheath tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the clinical response rate (complete and partial) in patients with sporadic or
           neurofibromatosis type 1 (NF1)-associated high-grade stage III or IV malignant
           peripheral nerve sheath tumors (MPNSTs) after treatment with 4 courses of chemotherapy
           comprising doxorubicin hydrochloride and ifosfamide (IA) followed by etoposide and
           ifosfamide (IE).

      Secondary

        -  Evaluate the utility of fludeoxyglucose F18 positron emission tomography (^18FDG-PET)
           and automated MRI volumetric tumor analysis as tools to assess response to treatment.

        -  Correlate response evaluation by 2-dimensional WHO criteria, 1-dimensional RECIST
           criteria, ^18FDG-PET, and volumetric MRI with percent necrosis in tumor specimens from
           patients who undergo surgery for local control after chemotherapy.

        -  Evaluate the response of plexiform neurofibroma(s) (if present) to chemotherapy using
           WHO criteria and automated volumetric MRI analysis.

        -  Evaluate the molecular biology of sporadic and NF1-associated MPNSTs by performing a
           detailed pathologic analysis of tumor samples with the goal to analyze if markers can be
           identified that predict for response to chemotherapy or outcome.

        -  Construct a tissue microarray from submitted tumor samples, that will be used in the
           future to identify novel targets for treatment of MPNSTs.

        -  Assess if a serum biomarker can be identified, that predicts for the presence of a MPNST
           versus benign plexiform neurofibroma.

        -  Increase the knowledge of the epidemiology and clinical presentation of NF1-associated
           MPNSTs.

      OUTLINE: This is a multicenter study. Patients are stratified according to type of malignant
      peripheral nerve sheath tumor (MPNST) (sporadic MPNST vs neurofibromatosis type 1
      [NF1]-associated MPNST). Patients receive 1 of 2 treatment regimens depending on the location
      of the MPNST and tumor response to chemotherapy.

        -  Chemotherapy and local control by radiotherapy and surgery: Patients receive doxorubicin
           hydrochloride and ifosfamide (IA) chemotherapy comprising doxorubicin hydrochloride IV
           over 15 minutes on days 1 and 2 and ifosfamide IV over 1 hour on days 1-5. Treatment
           repeats every 21 days for 2 courses in the absence of unacceptable toxicity. Patients
           then receive etoposide and ifosfamide (IE) chemotherapy comprising etoposide IV over 1
           hour and ifosfamide IV over 1 hour on days 1-5. Treatment repeats every 21 days for 2
           courses in the absence of disease progression or unacceptable toxicity. Patients also
           receive filgrastim (G-CSF) subcutaneously (SC) after each chemotherapy course beginning
           on day 6 or 7 and continuing until blood counts recover or pegfilgrastim SC once on day
           6 or 7.

      After recovery from chemotherapy, patients undergo radiotherapy and receive 2 more courses of
      IE during radiotherapy followed by 2 more courses of IA after completion of radiotherapy.
      Some patients may then undergo surgery.

        -  Chemotherapy and local control by surgery: Patients receive 2 courses of IA followed by
           2 courses of IE as above. After recovery from chemotherapy, patients undergo surgery.
           After recovery from surgery, patients receive 2 more courses of IA followed by 2 more
           courses of IE in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed periodically for up to 5 years.

      PROJECTED ACCRUAL: A total of 74 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (Complete Response and Partial Response)</measure>
    <time_frame>After 4 Cycles (1 cycle=21 days)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Neurofibromatosis Type 1</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Chemotherapy and local control by radiotherapy and surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin hydrochloride and ifosfamide (IA) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity. Patients then receive etoposide and ifosfamide (IE) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim (G-CSF) subcutaneously (SC) after each chemotherapy course. After recovery from chemotherapy, patients undergo radiotherapy and receive 2 more courses of IE during radiotherapy followed by 2 more courses of IA after completion of radiotherapy. Some patients may then undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy and local control by surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2 courses of IA followed by 2 courses of IE as above. After recovery from chemotherapy, patients undergo surgery. After recovery from surgery, patients receive 2 more courses of IA followed by 2 more courses of IE in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Chemotherapy and local control by radiotherapy and surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemotherapy and local control by radiotherapy and surgery</arm_group_label>
    <arm_group_label>Chemotherapy and local control by surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemotherapy and local control by radiotherapy and surgery</arm_group_label>
    <arm_group_label>Chemotherapy and local control by surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemotherapy and local control by radiotherapy and surgery</arm_group_label>
    <arm_group_label>Chemotherapy and local control by surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Patients undergo surgery</description>
    <arm_group_label>Chemotherapy and local control by radiotherapy and surgery</arm_group_label>
    <arm_group_label>Chemotherapy and local control by surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Patients undergo radiotherapy</description>
    <arm_group_label>Chemotherapy and local control by radiotherapy and surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Newly diagnosed sporadic or neurofibromatosis type 1 (NF1)-associated high-grade
             malignant peripheral nerve sheath tumors (MPNSTs)

               -  Stage III or stage IV (metastatic) disease

          -  Measurable disease, defined as at least 1 tumor that is measurable in 2 dimensions on
             CT scan or MRI

        PATIENT CHARACTERISTICS:

          -  Ejection fraction normal by echocardiogram or MUGA

          -  Serum creatinine normal for age OR creatinine clearance &gt; 60 mL/min

          -  SGPT &lt; 5 times upper limit of normal (ULN)

          -  Bilirubin &lt; 2.5 times ULN

          -  Absolute neutrophil count ≥ 1,500/mm^3*

          -  Hemoglobin ≥ 9.0 g/dL*

          -  Platelet count ≥ 100,000/mm^3*

          -  ECOG performance status 0-2

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after
             completion of study treatment NOTE: * Unsupported

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy for MPNST

          -  Prior surgical resection of MPNST allowed provided residual or recurrent measurable
             disease is present

          -  Recovered from toxic effects of all prior therapy

          -  At least 3 weeks since prior chemotherapy or biologic therapy for treatment of a
             plexiform neurofibroma, optical pathway tumor, or other NF1-associated tumor (in
             patients with NF1)

          -  At least 6 weeks since prior radiotherapy for treatment of a plexiform neurofibroma,
             optical pathway tumor, or other NF1-associated tumor (in patients with NF1)

          -  At least 4 weeks since prior radiotherapy to the area involved by MPNST

          -  No other concurrent growth factors (e.g., sargramostim [GM-CSF] or interleukin-11)

               -  Concurrent epoetin alfa allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte C. Widemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Hematology-Oncology Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Oncology Hematology Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute at University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance at Washington University</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <results_first_submitted>April 16, 2018</results_first_submitted>
  <results_first_submitted_qc>April 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2018</results_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult neurofibrosarcoma</keyword>
  <keyword>childhood neurofibrosarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>neurofibromatosis type 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neurofibrosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NF1 MPNST</title>
          <description>2 cycles of ifosfamide + doxorubicin (‘IA’) followed by 2 cycles of ifosfamide + etoposide (‘IE’) prior to local control measures (surgery and/or radiation therapy).
Local control with surgery and/or radiation will commence after recovery from toxicities. Patients, who undergo surgery only, will receive 2 more cycles of ‘IA’ followed by 2 cycles of ‘IE’ beginning after recovery from surgery. Patients, who receive radiation therapy in addition to surgery, will receive 2 cycles of ‘IE’ during radiation treatment, as doxorubicin cannot be concurrently administered with radiation therapy, and 2 cycles of ‘IA’ after completion of radiation treatment.
1 cycle = 21 days Doxo = Doxorubicin 37.5 mg/m2/dose IV over 15 minutes on days 1, 2 Ifos = Ifosfamide 1,800 mg/m2/dose IV over 60 minutes on days 1, 2, 3, 4, 5 Etop = Etoposide 100 mg/m2/dose IV over 60 minutes on days 1, 2, 3, 4, 5</description>
        </group>
        <group group_id="P2">
          <title>Sporadic MPNST</title>
          <description>2 cycles of ifosfamide + doxorubicin (‘IA’) followed by 2 cycles of ifosfamide + etoposide (‘IE’) prior to local control measures (surgery and/or radiation therapy).
Local control with surgery and/or radiation will commence after recovery from toxicities. Patients, who undergo surgery only, will receive 2 more cycles of ‘IA’ followed by 2 cycles of ‘IE’ beginning after recovery from surgery. Patients, who receive radiation therapy in addition to surgery, will receive 2 cycles of ‘IE’ during radiation treatment, as doxorubicin cannot be concurrently administered with radiation therapy, and 2 cycles of ‘IA’ after completion of radiation treatment.
1 cycle = 21 days Doxo = Doxorubicin 37.5 mg/m2/dose IV over 15 minutes on days 1, 2 Ifos = Ifosfamide 1,800 mg/m2/dose IV over 60 minutes on days 1, 2, 3, 4, 5 Etop = Etoposide 100 mg/m2/dose IV over 60 minutes on days 1, 2, 3, 4, 5</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 4 Cycles</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Neurofibromatosis Type 1- (NF1-) Associated</title>
          <description>Patients received 2 cycles of doxorubicin and ifosfamide followed by 2 cycles of ifosfamide and etoposide.</description>
        </group>
        <group group_id="B2">
          <title>Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)</title>
          <description>Patients received 2 cycles of doxorubicin and ifosfamide followed by 2 cycles of ifosfamide and etoposide.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="8" upper_limit="66"/>
                    <measurement group_id="B2" value="40" lower_limit="13" upper_limit="72"/>
                    <measurement group_id="B3" value="36.5" lower_limit="8" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (Complete Response and Partial Response)</title>
        <time_frame>After 4 Cycles (1 cycle=21 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neurofibromatosis Type-1 Associated</title>
            <description>NF1 associated MPNST</description>
          </group>
          <group group_id="O2">
            <title>Sporadic MPNST</title>
            <description>Sporadic MPNST</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (Complete Response and Partial Response)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NF-1 and Sporadic MPNST</title>
          <description>NF-1 Associated and Sporadic MPNST combined</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Secondary acute myeloid leukemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <description>Eight patients had dose reductions of chemotherapy with three of those being for neurotoxicity associated with ifosfamide.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Project Manager</name_or_title>
      <organization>SARC</organization>
      <phone>734-930-7600</phone>
      <email>sarc@sarctrials.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

